We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why McKesson (MCK) Fell More Than Broader Market
Read MoreHide Full Article
McKesson (MCK - Free Report) closed the most recent trading day at $910.33, moving -1.23% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.66%, and the technology-dominated Nasdaq saw a decrease of 0.22%.
Coming into today, shares of the prescription drug distributor had gained 3.66% in the past month. In that same time, the Medical sector lost 4.73%, while the S&P 500 gained 1.4%.
Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. The company is predicted to post an EPS of $10.8, indicating a 9.53% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $110.14 billion, indicating a 6.78% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $44.73 per share and revenue of $429.01 billion, which would represent changes of +14.37% and +6.34%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for McKesson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.18% rise in the Zacks Consensus EPS estimate. McKesson presently features a Zacks Rank of #2 (Buy).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 20.6. This indicates a premium in contrast to its industry's Forward P/E of 17.22.
Investors should also note that MCK has a PEG ratio of 1.83 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.9.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 78, finds itself in the top 32% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MCK in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why McKesson (MCK) Fell More Than Broader Market
McKesson (MCK - Free Report) closed the most recent trading day at $910.33, moving -1.23% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.66%, and the technology-dominated Nasdaq saw a decrease of 0.22%.
Coming into today, shares of the prescription drug distributor had gained 3.66% in the past month. In that same time, the Medical sector lost 4.73%, while the S&P 500 gained 1.4%.
Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. The company is predicted to post an EPS of $10.8, indicating a 9.53% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $110.14 billion, indicating a 6.78% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $44.73 per share and revenue of $429.01 billion, which would represent changes of +14.37% and +6.34%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for McKesson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.18% rise in the Zacks Consensus EPS estimate. McKesson presently features a Zacks Rank of #2 (Buy).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 20.6. This indicates a premium in contrast to its industry's Forward P/E of 17.22.
Investors should also note that MCK has a PEG ratio of 1.83 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.9.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 78, finds itself in the top 32% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MCK in the coming trading sessions, be sure to utilize Zacks.com.